Bio-Matrix's Chairman and CEO David Koos Summarizes the Sale of Its Wholly Owned Subsidiary and Operating Entity to Tasco Holdings International, Inc. in Online Audio Interview.

SAN DIEGO -- Bio-Matrix Scientific Group, Inc., a Delaware corporation (Pink Sheets:BMXP), a biotechnology company focused on stem cell cryogenics and disposable stem cell / tissue transfer instruments, (http://www.bmxgonline.com), announced today that its Chairman and CEO, David R. Koos, was the key speaker on Agoracom's CEO Interview. This interview can be heard in its entirety at http://www.agoracom.com/nonmemforum/broadcast.asp.

In the interview, Mr. Koos summarized the sale of BMXP's wholly owned subsidiary and operating entity, Bio-Matrix Scientific Group, Inc., a Nevada corporation ("BMSG Nevada") to Tasco Holdings International, Inc. (OTCBB:THII) that is scheduled to close July 1, 2006.

Mr. Koos stated that both Tasco and BMXP anticipate that each will, by shareholder action, subsequently change their corporate name following the closing of the transaction and, in the case of Tasco, in accordance with the requirements of Section 14C of the Securities Exchange Act of 1934. These plans call for Tasco to change its name to Bio-Matrix Scientific Group Inc. and for BMXP (the Pink Sheet Company) that currently carries that corporate name, to change its name to avoid confusion.

BMXP, a Delaware corporation, is currently known under its corporate name, Bio-Matrix Scientific Group, Inc. BMXP anticipates that it will continue to trade on the Pink Sheets and will become, upon closing of the transaction with Tasco, the largest shareholder of Tasco holding approximately 78% of the outstanding shares of Tasco.

As currently planned, BMXP intends to file a registration statement with the SEC to register the Tasco shares it acquired in the transaction under the Securities Act of 1933 and distribute those shares to BMXP shareholders as a dividend upon effectivity of the registration statement. The record date for the planned dividend distribution has not been established by BMXP's Board of Directors.

Mr. Koos also stated that the sale of BMSG Nevada subsidiary to Tasco was motivated in part because Tasco's common stock is traded on the OTC Bulletin Board. He noted that the OTC Bulletin Board is viewed as offering the potential for greater access to institutional investors. "On the Bulletin Board, the company will be more transparent to potential institutional investors. We believe that institutional investors are important to the company, as they may be able to facilitate a more rapid implementation of the business model and potential future revenues streams."

Mr. Koos also updated the status of BMSG Nevada's new Stem Cell Cryogenic facility, "Currently, the processing laboratory is under construction and should, based on our current estimates, be completed by the end of August 2006. Once completed, the facility will undergo extensive testing. The Class 10,000 clean room labs should be completed by the end of August 2006. The company currently anticipates that if third party commitments the company has received remain on schedule, the company believes it will be ready for specimens in the first part of the 4th quarter of 2006."

This press release is available on the company's official online Investor Relations HUB at http://www.agoracom.com/IR/Bio-Matrix for investor questions, answers and monitored commentary. Alternatively, investors are able to e-mail all questions and correspondence to [e-mail] where they can also request addition to the investor e-mail list to receive all future press releases and updates in real time.

About Bio-Matrix Scientific Group Inc.

Bio-Matrix Scientific Group Inc. is a development stage company that seeks to enter the business of developing medical devices and monitoring systems research, development and commercialization.

Bio-Matrix Scientific Group Inc. seeks to align itself with partners that may offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems. Other companies in the same industry as Bio-Matrix Scientific Group Inc. (Pink Sheets:BMXP) include Cord Blood America (OTCBB:CBAI), StemCells Inc. (NASDAQ:STEM) and Regeneration Technologies (OTCBB:RTIX). More information will be available shortly on the Company's website: www.BMXGonline.com

THIS PRESS RELEASE AND THE INFORMATION CONTAINED ON THE COMPANY'S WEB SITE CONTAINS "FORWARD-LOOKING STATEMENTS" THAT CAN BE IDENTIFIED BY THE USE OF FORWARD-LOOKING WORDS SUCH AS "BELIEVES," "EXPECTS," "MAY," "WILL," "SHOULD," OR "ANTICIPATES," OR COMPARABLE WORDS, OR BY DISCUSSIONS OF PLANS OR STRATEGY. THESE STATEMENTS INVOLVE RISKS AND UNCERTAINTIES. THE COMPANY WISHES TO CAUTION THE READER THAT THESE FORWARD-LOOKING STATEMENTS, INCLUDING, BUT NOT LIMITED TO, STATEMENTS REGARDING THE COMPANY'S PLANS, GOALS, THE OPPORTUNITIES THAT THE COMPANY MAY ACHIEVE WITH INSTITUTIONAL INVESTORS, THE OTC BULLETIN BOARD MARKET AND OTHER MATTERS THAT ARE NOT HISTORICAL FACTS ARE ONLY PREDICTIONS. NO ASSURANCES CAN BE GIVEN THAT SUCH PREDICTIONS WILL PROVE CORRECT OR THAT THE ANTICIPATED FUTURE RESULTS WILL BE ACHIEVED. ACTUAL EVENTS OR RESULTS MAY DIFFER MATERIALLY EITHER BECAUSE ONE OR MORE PREDICTIONS PROVE TO BE ERRONEOUS OR AS A RESULT OF OTHER RISKS FACING THE COMPANY. FORWARD-LOOKING STATEMENTS SHOULD BE READ IN LIGHT OF THE CAUTIONARY STATEMENTS THAT TASCO LISTED IN THE FORM 8-K IT FILED ON JUNE 14, 2006. FOR BIO-MATRIX SCIENTIFIC GROUP, INC., THE RISKS INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS ASSOCIATED WITH AN EARLY-STAGE COMPANY THAT HAS ONLY A LIMITED HISTORY OF OPERATIONS, THE COMPARATIVELY LIMITED FINANCIAL RESOURCES OF THE COMPANY, THE INTENSE COMPETITION THE COMPANY FACES FROM OTHER LARGER COMPETITORS, TECHNOLOGICAL CHANGES THAT MAY LIMIT THE ABILITY OF THE COMPANY TO MARKET AND SELL ITS PRODUCTS AND SERVICES. WE UNDERTAKE NO OBLIGATION TO UPDATE OR REVISE ANY FORWARD-LOOKING STATEMENT TO REFLECT EVENTS, CIRCUMSTANCES, OR NEW INFORMATION AFTER THE DATE OF THIS PRESS RELEASE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED OR OTHER SUBSEQUENT EVENTS.